Alayo, Quazim A.
Ito, Hirotaka
Passaro, Carmela
Zdioruk, Mykola
Mahmoud, Ahmad Bakur
Grauwet, Korneel
Zhang, Xiaoli
Lawler, Sean E.
Reardon, David A.
Goins, William F.
Fernandez, Soledad
Chiocca, E. Antonio
Nakashima, Hiroshi
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (2P01CA163205, 2P01CA163205, 5P01CA069246, 2P01CA163205)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 4 September 2019
Accepted: 20 February 2020
First Online: 20 March 2020
Competing interests
: E.A.C. is currently a paid advisor to Advantagene Inc., Insightec, Inc., and DNAtrix Inc. and has equity interest in DNAtrix; He has received research support from Advantagene, NewLink Genetics and Amgen. H.N. has received research support from NewLink Genetics. H.N. was a technical consultant for Oncorus INC and has received compensation. W.F.G is a consultant for Oncorus INC and has received compensation. D.A.R. (DFCI) has received research support from Acerta Phamaceuticals; Agenus; Celldex; EMD Serono; Incyte; Inovio; Midatech; Omniox; Tragara. D.A.R. is currently paid advisory/consultant for Abbvie; Advantagene; Agenus; Amgen; Bayer; Bristol-Myers Squibb; Celldex; DelMar; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc. Other authors declare no competing interests. E.A.C. has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanaghai Biotech. H.N. and E.A.C are named inventors on patents related to oncolytic HSV1.